Edition:
United States

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

8.85USD
21 May 2018
Change (% chg)

$-0.05 (-0.56%)
Prev Close
$8.90
Open
$8.85
Day's High
$8.85
Day's Low
$8.85
Volume
472
Avg. Vol
7,588
52-wk High
$9.20
52-wk Low
$5.70

Chart for

About

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies,... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $124.63
Shares Outstanding(Mil.): 14.16
Dividend: --
Yield (%): --

Financials

  CEMI.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -0.52 -- --
ROI: -41.52 13.08 12.63
ROE: -42.13 14.80 14.50

BRIEF-Chembio Diagnostics Reports Q1 Loss Per Share $0.05

* CHEMBIO DIAGNOSTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Chembio Diagnostics And Lumiradx Enter Collaboration To Develop New Point-Of-Care Diagnostic Tests For Infectious Diseases

* CHEMBIO DIAGNOSTICS AND LUMIRADX ENTER COLLABORATION TO DEVELOP NEW POINT-OF-CARE DIAGNOSTIC TESTS FOR INFECTIOUS DISEASES

Apr 25 2018

BRIEF-Chembio Diagnostics Q4 Loss Per Share $0.16

* CHEMBIO DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Chembio Diagnostics Announces Proposed Public Offering Of Common Stock

* CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 08 2018

BRIEF-Chembio Diagnostics Announces Major New Tender Win And Certain Preliminary 2017 Financial Results

* CHEMBIO DIAGNOSTICS ANNOUNCES MAJOR NEW TENDER WIN AND CERTAIN PRELIMINARY 2017 FINANCIAL RESULTS

Feb 08 2018

BRIEF-Chembio Diagnostics Appoints Neil Goldman As CFO

* CHEMBIO DIAGNOSTICS ANNOUNCES APPOINTMENT OF NEIL A. GOLDMAN AS CHIEF FINANCIAL OFFICER

Dec 20 2017

BRIEF-Chembio Diagnostics And Astrazeneca Collaborates To Develop Point-Of-Care Diagnostic Test

* CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST

Dec 19 2017

BRIEF-Chembio receives $8.5 mln commitment from Bio-Manguinhos to purchase components for production of dpp Assays in Brazil during 2018

* CHEMBIO RECEIVES $8.5 MILLION COMMITMENT FROM BIO-MANGUINHOS TO PURCHASE COMPONENTS FOR PRODUCTION OF DPP® ASSAYS IN BRAZIL DURING 2018

Dec 05 2017

BRIEF-Chembio Diagnostics Awarded UNICEF Contract

* CHEMBIO DIAGNOSTICS AWARDED UNICEF CONTRACT TO SUPPLY POINT-OF-CARE DPP® ZIKA ASSAYS AND DPP® MICRO READERS

Nov 28 2017

Competitors

Earnings vs. Estimates